Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $1.92 Million Stake in Edwards Lifesciences Corporation $EW

Empirical Financial Services LLC d.b.a. Empirical Wealth Management trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 0.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,516 shares of the medical research company’s stock after selling 217 shares during the quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Edwards Lifesciences were worth $1,917,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of EW. Arlington Trust Co LLC grew its holdings in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock worth $804,000 after purchasing an additional 135 shares during the last quarter. Valeo Financial Advisors LLC grew its holdings in shares of Edwards Lifesciences by 2.8% in the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock worth $372,000 after purchasing an additional 142 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after purchasing an additional 145 shares during the last quarter. Dakota Wealth Management grew its holdings in shares of Edwards Lifesciences by 2.5% in the 2nd quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company’s stock worth $473,000 after purchasing an additional 146 shares during the last quarter. Finally, Leo Wealth LLC grew its holdings in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Leo Wealth LLC now owns 12,488 shares of the medical research company’s stock worth $905,000 after purchasing an additional 150 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $77.03 on Friday. The stock has a 50-day moving average price of $78.50 and a 200 day moving average price of $75.94. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm has a market cap of $45.22 billion, a price-to-earnings ratio of 11.08, a PEG ratio of 3.69 and a beta of 1.05. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the business earned $0.70 earnings per share. The company’s revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on EW shares. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Stifel Nicolaus set a $85.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research note on Monday, September 22nd. Deutsche Bank Aktiengesellschaft raised their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, July 25th. Finally, Truist Financial raised their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a research note on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $86.61.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.